Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery-2

endometrioid origin (as shown) were diluted in binding buffer, coated on plastic wells, and detected with polyclonal antibodies made to the center (pAb, white bars) or N-terminal (pAb, gray bars) region of PEBP1 or with a pAb made to the whole recombinant protein (black bars). Samples were tested in triplicates. Averages are shown. Wells coated with binding buffer were used as negative controls.<p><b>Copyright information:</b></p><p>Taken from "Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery"</p><p>http://www.translational-medicine.com/content/6/1/41</p><p>Journal of Translational Medicine 2008;6():41-41.</p><p>Published online 24 Jul 2008</p><p>PMCID:PMC2503970.</p><p></p

Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery-1

Trophoresis before (lanes 1,3) or after (lanes 2,4) depletion for abundant proteins by cibacron blue and detected by coomassie blue straining. B-C: Control- and ovarian cancer-pool serum depleted for abundant sequences were immunoprecipitated with biobodies selected for specific binding to case-pool serum. The products of elution from control sera (B lane 2, and C) and ovarian cancer (B lane 1, and D) were separated by 1-D (B) or 2-D (C,D) protein electrophoresis and detected by silver staining. In the 2-D gels, the immunoprecipitates were focused over a pH3 to pH10 range and run on a 10% acrylamide gel. The circle indicates the region where PEBP1 was found in patient serum (D) but not in control serum (C).<p><b>Copyright information:</b></p><p>Taken from "Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery"</p><p>http://www.translational-medicine.com/content/6/1/41</p><p>Journal of Translational Medicine 2008;6():41-41.</p><p>Published online 24 Jul 2008</p><p>PMCID:PMC2503970.</p><p></p

Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery-4

bound to case-pool serum. The enriched yeast-display scFv were labeled with anti-c-myc mAb and 25 μg/ml (A,B,E,F) or 100 μg/ml (C,D,G,H) of biotinylated case (A,C,E,G) or control (B,D,F,H) serum pools, before (A-D) or after depletion by magnetic sorting (E-H). Binding signals were detected as shown with the secondary antibody 488-alexa anti-mouse Ig (488 anti-mIg) and PE-labeled streptavidin (SA-PE).<p><b>Copyright information:</b></p><p>Taken from "Use of cancer-specific yeast-secreted biotinylated recombinant antibodies for serum biomarker discovery"</p><p>http://www.translational-medicine.com/content/6/1/41</p><p>Journal of Translational Medicine 2008;6():41-41.</p><p>Published online 24 Jul 2008</p><p>PMCID:PMC2503970.</p><p></p